PET scan imaging in oncology.
With the emergence of positron emission tomography (PET) from research laboratories into routine clinical use, it is important to redefine the most appropriate use of each imaging technique. The aim of this review article is to show the potential of PET in oncology. We discuss the most promising indications and the perspectives for the future. We will also point out the shortcomings and the important questions to be answered before fully considering PET as a necessary tool in the day-to-day practice of oncology. Although many studies have documented the high accuracy of 18F-FDG PET for the detection and staging of malignant tumours and for the monitoring of therapy results in these patients, it is very important to assess the impact of the technique on patient outcome and to show cost-effectiveness from the societal viewpoint.
Jerusalem
G
G
Department of Medicine, Division of Medical Oncology and Hematology, CHU Sart Tilman, B35, B-4000-Liege 1, Belgium. g.jerusalem@chu.ulg.ac.be
Hustinx
R
R
Beguin
Y
Y
Fillet
G
G
D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D009367:Neoplasm Staging / Q000379:methods; D009369:Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18